Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients
Foot Ulcer
About this trial
This is an interventional treatment trial for Foot Ulcer
Eligibility Criteria
Inclusion Criteria: Type 1 or Type 2 diabetes mellitus Age>= 18 years Study wound is a Wagner Grade 1 partial thickness or Grade 2 full thickness lesion but without exposed tendon, joint, or bones Study wound located on the foot or lower leg Study wound must have been present for at least 4 weeks prior to Day 0 but not longer than 2 years Adequate circulation to the foot, evidenced by a palpable pulse on the study foot Study wound > 1.0cm2 but < 20.0cm2 Written informed consent Exclusion Criteria: Pregnancy, lactation or absence of adequate contraception for fertile women Ankle/Brachial Index < 0.7 Severe malnutrition Clinical evidence of gangrene on any part of the foot with the study wound Active or extensive cellulitis extending more than 1 cm beyond wound margin and/or presence of cellulitis with purulent discharge on day 0 One or more medical condition(s) that in the opinion of the investigator would make the patient an inappropriate candidate for the study Active osteomyelitis of the foot with the study wound Necrotic toes on the foot with the study wound Surgical procedure (other than debridement) on the foot with the study wound the last 21 days prior to screening Study wound over a Charcot's joint Evidence of deep tissue infection of the study wound at day 0 Non-study wound on the study foot that is located within 5.0cm from the study wound at day 0 Random blood sugar reading > 450 mg/dL Alcohol or drug abuse Participation in other clinical studies in the last 4 weeks
Sites / Locations
- Municipal Healthcare Institution 1st City Clinical Hospital
- St. Petersburg State Institution Saint Martyr Elezabeth Hospital